Biocon
Biocon Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).
From Biocon's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. Four biosimilars each crossed USD 200 million revenue, indicating strong adoption and future growth. (Pages 6, 13, 17)
- Generics: Growth supported by multiple upcoming product launches including liraglutide in Europe and the U.S., generic Copaxone, Everolimus (Zortress), and continued volumes from generic lenalidomide starting FY '26. (Pages 15, 10)
- Insulin: Significant surge in global demand with capacity doubling in Malaysia; poised to become one of the largest fully integrated insulin manufacturers. Innovators withdrawing from certain markets opens opportunities. (Pages 15, 17, 13)
- GLP-1s: Peptide portfolio, especially GLP-1s, expected to be key future growth drivers with ongoing capacity expansions. (Page 6, 15)
- Overall: From FY '25 to '30, the company aims to launch around one new product per year, sustaining growth momentum. (Page 17)
Profitability & Margins
See what Biocon said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).
- A large part of this Capex focuses on increasing insulin manufacturing capacity, including a twofold expansion of drug product and drug substance capacities in Malaysia (Page 15).
- For Generics, next year’s Capex is estimated at around USD 50 million, mostly maintenance Capex, with major ongoing programs concluding (Page 14).
- Investment in large-scale drug substance capacity for GLP-1s was capitalized in FY'25, and a new injectable GLP-1 facility will be commissioned in FY'26; capacity expansions planned beyond 2031 based on market demand (Page 16).
- Syngene acquired a state-of-the-art biologics facility in the U.S., expanding its global CDMO manufacturing footprint (Page 7).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Biocon said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Biocon — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Biocon Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
- Strides Pharma Science Ltd (Q4 FY25)
Other regulated markets like Europe have steadied with 13.5% growth and product launches driven by partnerships. Key concall takeaways from Strides Pharma…
Frequently Asked Questions
What were Biocon Q4 FY25 results?
Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).
What is Biocon share price analysis?
Biocon currently shows a neutral. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.
Is Biocon planning capital expenditure?
Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).
Keep Biocon on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.